Navigation Links
Sygnis Pharma AG announces date for presentation of clinical,results

HEIDELBERG, Germany, 11 July 2007 – On 23 July SYGNIS Pharma AG will present the results of the clinical phase IIa study for AX200 (AXIS-study).

AX200, a compound for the treatment of stroke, is the most advanced drug candidate in SYGNIS’ product pipeline. The primary aim of the study is to show safety and tolerability of AX200 in acute stroke patients. The results of the AXIS-study are expected to provide information for the further clinical development of AX200.

Furthermore, the company announces that this year’s Annual General Meeting will take place on 28 November 2007 in Eppelheim.

About SYGNIS Pharma

SYGNIS Pharma AG, with head offices in Heidelberg, is a specialist pharmaceutical company listed on the Prime Standard of the German stock exchange. The company is focusing on the research, development and marketing of innovative therapies for the treatment of neurodegenerative diseases. These include stroke, Amyotrophic Lateral Sclerosis (ALS), Huntington's Disease or neurological disorders resulting from injury, such as trauma of the brain or spinal cord. All these disorders are characterised by the fact that, as the disease progresses, nerve cells die off. Although there is a great medical demand, there are currently no or only inadequate treatment options available.

In its drug development, the company has taken a completely novel approach: it develops compounds that protect nerve cells in the acute phase of the disease, and beyond that, also stimulate the regeneration of the damaged nervous system.

For more information, please contact:

Dr. Franz-Werner Haas Vice President Operations +49 (0) 6221 454 812 franz-werner.haas@sygnis.de

### Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as f
'"/>




Page: 1 2

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
11. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Sygnis Pharma announces date for presentation clinical results
(Date:10/22/2014)...  Cephasonics, a technology-innovation leader with a game-changing embedded-ultrasound ... Ultrasound Box™-1), the first product in a new family ... Cephasonics for purchase by companies to rebrand with their ... showcasing the cQUB-1 for the first time at CMEF ... Chongqing, China from October 23 to 26. ...
(Date:10/22/2014)... , Oct. 22, 2014  Charlene Vernak, RPh, of Vernak ... , recently was awarded the George Roentsch Scholarship by ... the award in Houston during ... is awarded annually to an independent pharmacist and PCCA ... George Roentsch , a well-known pharmacist in the ...
(Date:10/22/2014)... October 22, 2014 A new ... Market (Product type, Form, End user, Application and Geography) ... Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - ... market. Based on key trends tracked, it is anticipated ... $7.9 billion by 2020, registering a CAGR of 6.2% ...
Breaking Medicine Technology:Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 3PCCA Awards Charlene Vernak, RPh, the George Roentsch Scholarship 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4
... Manzanita Senior Center today aims to inform older adults about ... plays in helping to improve the body,s immune response against ... typically the hardest hit by influenza, according to the U.S. ... launching in the Phoenix area today, called Influenza Immunization ...
... In today,s quality-driven healthcare environment, oncologists balance a ... the ongoing business success of their practice. Today, ... McKesson Corporation , announced that through its ... offering Innovative Practice Services to help oncology practices ...
Cached Medicine Technology:Influenza Awareness Initiative for Phoenix Seniors Highlights Need for Influenza Vaccination for Adults Age 65 and Older 2New McKesson Specialty Health Program Helps Providers Thrive In Today's Quality-Driven Healthcare Environment 2New McKesson Specialty Health Program Helps Providers Thrive In Today's Quality-Driven Healthcare Environment 3
(Date:10/22/2014)... October 22, 2014 Hay House is pleased ... Addiction and Upgrade Your Life (Paperback; $10.82) written by the ... & Recovery. This book is meant to help readers ... life of recovery. , Recovery 2.0 is not the ... Recovery 2.0 is a guide for what comes next. ...
(Date:10/22/2014)... 22, 2014 Healthcare professionals who ... continuing education at home or on-the-go via laptops, ... 20 brand new, premium Seminar-on-Demand CE courses. The ... over 2,000 hours of CE course ... educational experience. With such a diverse library, there’s ...
(Date:10/22/2014)... 2014 Richard Carlson, Managing Partner of ... with over 25 years experience. Mr. Carlson is ... areas related to EDI, B2B Commerce, RFID and Internet/Intranet ... Advisory Board member for Pharmaceutical Commerce Magazine and a ... Group is a management and technology consulting firm focused ...
(Date:10/22/2014)... sisters in high school have developed ways to measure ... use electronic stethoscopes, which electronically amplify body sounds, to ... heartbeats. Ilina, a senior at Port Huron Northern ... to detect early lung damage in people exposed to ... one breath cycle each from 16 smokers, 25 nonsmokers ...
(Date:10/22/2014)... HealthDay Reporter , MONDAY, Oct. 20, 2014 (HealthDay ... for health workers treating Ebola patients, now requiring full body ... at all times. The U.S. Centers for Disease Control ... Dallas nurses contracted Ebola while caring for the first ... Duncan. Nina Pham is currently being treated for her infection ...
Breaking Medicine News(10 mins):Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3
... by the Food & Drug Administration for the treatment of prostate ... A new study shows abiraterone acetate extends the lives of ... four months. The study in the May 26, 2011 issue of ... Thomas W. Flaig, MD, medical oncologist at the University of Colorado ...
... Calif. A woman,s risk of developing diabetes during pregnancy ... pregnant based on routinely assessed measures of blood sugar and ... the online issue of the American Journal of Obstetrics ... Kaiser Permanente Division of Research in Oakland, Calif., studied 580 ...
... traumatic stress with war-afflicted populations (veterans and civilians) and ... research professor in the department of psychology and the ... the University of Houston (UH), decided to study another ... eighth grade. "Teaching is a highly stressful ...
... , WEDNESDAY, May 25 (HealthDay News) -- Taken in ... the cholesterol-lowering medication Pravachol, appear to significantly raise blood ... is most apparent -- and concerning -- among diabetics, ... noted. "This interaction may affect as many as ...
... field, poised to take a crucial penalty kick, "I always had a ... do" says sports psychologist Antonis Hatzigeorgiadis. "I was setting the ball and ... of shots; then I had that thought striking me that it was ... he recalls, "and I did miss." Even then, he could see that ...
... Medications are the mainstay of treatment for epilepsy, but for ... many as 1 million in the U.S. drugs don,t ... as refractory or drug-resistant epilepsy, in which drugs can,t control ... last month, Dr. Christopher DeGiorgio, a UCLA professor of neurology, ...
Cached Medicine News:Health News:New drug treatment extends lives of men with prostate cancer 2Health News:Diabetes can be predicted 7 years before pregnancy with blood sugar and body weight 2Health News:New University of Houston research study links job stress in teachers to student achievement 2Health News:New University of Houston research study links job stress in teachers to student achievement 3Health News:Combo of Paxil, Pravachol May Raise Blood Sugar 2Health News:Combo of Paxil, Pravachol May Raise Blood Sugar 3Health News:Thoughts that win 2Health News:Unique nerve-stimulation treatment proves effective against drug-resistant epilepsy 2
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
Inquire...
Medicine Products: